Nicotinic Acid Plus Laropiprant Suspended for Dyslipidaemia

Susan Mayor

DOI: https://doi.org/10.1016/s2213-8587(13)70129-3

IF: 44.867

2013-01-01

The Lancet Diabetes & Endocrinology

Abstract:The European Medicines Agency (EMA) has recommended suspending marketing authorisations for medicines containing a combination of nicotinic acid and laropiprant for the treatment of adults with dyslipidaemia after a study did not meet its primary endpoint and showed increased risk of serious adverse events. “Doctors should no longer prescribe these medicines and should review patients' treatment options”, said the agency's Committee for Medicinal Products for Human Use in a statement published on Jan 18, 2013. Its review of the combination of nicotinic acid and laropiprant followed release of data from the Heart Protection Study 2 – Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) study in December, 2012. The study, run by the University of Oxford's Clinical Trial Service Unit, UK, compared extended release nicotinic acid (also known as niacin) and laropiprant plus statin treatment with statin treatment alone in 25 673 patients at high risk for cardiovascular events. Just over a quarter (26%) of the European participants and 42% of study patients recruited in China had type 2 diabetes. The aim was to investigate whether raising HDL cholesterol with nicotinic acid plus laropiprant reduced the risk of heart attack and stroke. Nicotinic acid lowers LDL cholesterol concentration and increases HDL cholesterol concentration by mechanisms that are not fully understood, but its use has been limited by side-effects, particularly skin flushing. Laropiprant reduces this flushing. “The preliminary HPS2-THRIVE results show that, when added to an effective statin-based treatment, the combination of extended release niacin and laropiprant does not produce clinically meaningful reductions in the rate of major vascular events”, said Jane Armitage, Professor of clinical trials and epidemiology at the University of Oxford and lead investigator of the study. There was also a statistically significant increase in the incidence of serious non-fatal adverse events in the group treated with extended release nicotinic acid plus laropiprant, Merck said in a statement. These included bleeding (intracranial and gastrointestinal), myopathy, infections, and new-onset type 2 diabetes. Having reviewed the study results, the Committee for Medical Products for Human Use concluded that the benefits of Tredaptive, Pelzont, and Trevalcyn (the brand names under which the combination of nicotinic acid and lapopiprant are marketed in different countries by Merck Sharp & Dohme) no longer outweighed the risks, and recommended that their marketing authorisations be suspended. The committee's opinion was sent to the European Commission, which suspended the supply of the medicines across the European Union.